TIDMIXI

RNS Number : 2350G

IXICO plc

18 July 2023

18 July 2023

IXICO plc

("IXICO", the "Company" or the "Group")

Contract win for a Phase 3 Progressive Supranuclear Palsy (PSP) study;

IXICO plc (AIM: IXI), the medical imaging advanced analytics company delivering intelligent insights in neuroscience, announces that it has signed a contract with a new client. IXICO will provide its imaging services in a clinical trial of a novel therapeutic to treat Progressive Supranuclear Palsy, a rare neurodegenerative disease. The contract value is circa US$1.7m (circa GBP1.3m), over a 4-year term. The World Health Organization defines a rare disease as one that strikes fewer than 65 per 100,000 people.

Giulio Cerroni, CEO of IXICO, commented: " Rare diseases are a global health priority with about 95% of all rare diseases not yet having treatments . This new contract exemplifies the traction we are building beyond our strong market position in HD into other rare neuro disorders to expand our market opportunities and acquire new clients in the dynamic field of rare neurological diseases(1) ."

(1) National Organisation of Rare Diseases

For further information please contact:

 
IXICO plc                                               +44 (0)20 3763 7499 
 
  Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 
Cenkos Securities PLC (Nominated adviser 
 and sole broker)                           +44 (0)20 7397 8900 
 
  Giles Balleny / Max Gould (Corporate 
  Finance) 
Michael F Johnson / Tamar Cranford-Smith 
 (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTUBOKRONUBARR

(END) Dow Jones Newswires

July 18, 2023 02:00 ET (06:00 GMT)

Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ixico Charts.
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ixico Charts.